Repligen (NASDAQ:RGEN) Posts Earnings Results, Beats Estimates By $0.10 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10, FiscalAI reports. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company posted $0.39 EPS. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen updated its FY 2026 guidance to 1.970-2.050 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen reported strong Q1 results with $194M revenue (15% reported, 11% organic), 160 bps adjusted operating margin expansion, and raised full‑year adjusted EPS guidance to $1.97–$2.05.
• Management launched a Transformation Office to accelerate cost, manufacturing and IT/AI improvements, targeting at least 1 point of annualized margin benefit by end‑2027 and advancing the path to 30% adjusted EBITDA by 2030 (with ~$5–6M of non‑recurring charges).
• China and Asia Pacific momentum picked up meaningfully—China revenues nearly doubled in Q1 and the company signed an OEM partnership to expand local manufacturing and competitiveness beginning in 2027.
• Franchise strength was broad‑based and higher‑margin—analytics grew 50%+ (now guided to 20%+ for 2026), chromatography rose >25% (now guided >20%), and proteins delivered mid‑teens growth with expectations of low double‑digit growth for the year.
• Filtration/ATF growth was moderated for 2026 due to specific customer timing and a gene‑therapy headwind; the divestiture of the loss‑making Polymem business removes about $7M of FY revenue even as it improves margin outlook.

Repligen Stock Performance

Shares of Repligen stock traded up $3.53 on Wednesday, reaching $129.14. 654,344 shares of the stock were exchanged, compared to its average volume of 878,289. Repligen has a 1-year low of $109.50 and a 1-year high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average price of $121.36 and a two-hundred day moving average price of $144.51. The firm has a market capitalization of $7.28 billion, a PE ratio of 151.93, a PEG ratio of 2.30 and a beta of 1.09.

Analysts Set New Price Targets

Several research firms have recently issued reports on RGEN. Barclays lifted their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Finally, Jefferies Financial Group restated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $170.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Federation des caisses Desjardins du Quebec increased its stake in shares of Repligen by 17.2% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,113 shares of the biotechnology company’s stock worth $674,000 after acquiring an additional 605 shares during the period. Sherbrooke Park Advisers LLC increased its stake in shares of Repligen by 28.0% during the third quarter. Sherbrooke Park Advisers LLC now owns 2,955 shares of the biotechnology company’s stock worth $395,000 after acquiring an additional 647 shares during the period. O Shaughnessy Asset Management LLC increased its stake in shares of Repligen by 37.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 2,335 shares of the biotechnology company’s stock worth $383,000 after acquiring an additional 630 shares during the period. Brooklyn Investment Group acquired a new position in shares of Repligen during the fourth quarter worth about $298,000. Finally, Guggenheim Capital LLC acquired a new position in shares of Repligen during the fourth quarter worth about $256,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q1 results topped expectations — Repligen reported $0.48 EPS vs. $0.38 consensus and revenue of ~$194M vs. $192M expected, driving the initial bullish move. Repligen’s Q1 Earnings & Revenues Beat Estimates, Stock Rises
• Positive Sentiment: Management set a multi‑year operating goal — Repligen is targeting a ~1 percentage‑point margin improvement by the end of 2027, which supports higher long‑term profitability expectations. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift
• Positive Sentiment: Operational/strategic moves may unlock upside — Coverage noted Repligen is reshaping operations and its China reach, which analysts see as supportive for valuation expansion if execution continues. Repligen Reshapes Operations And China Reach As Valuation Signals Upside
• Neutral Sentiment: FY‑2026 EPS guidance provided — Repligen gave an EPS range of $1.97–$2.05 for FY‑2026 (roughly in line with consensus), reducing one source of near‑term uncertainty but leaving revenue sensitivity. Repligen Reports First-Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
• Neutral Sentiment: Management commentary and full earnings transcript are available — Investors can review the call/transcript for details on backlog, regional demand and margin timing before adjusting positions. Repligen Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue guidance trims upside vs. consensus — Full‑year revenue was guided to $803M–$833M, with the midpoint below recent Street consensus (~$828M), creating some near‑term revenue risk that could cap gains if demand softens. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.